Cancer Clinical Trial -CSL Behring/Celegene- CSL964_2001

Status:

Open

ClinicalTrials.gov:

NCT03805789

Celgene JCAR017-BCM-003-The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) not enrolling

Drug

CSL964_2001

Phase

Phase ||/|||

Condition

Study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).

Keywords

Cellular therapy Graft Versus Host Disease | Bone marrow Transplant clinical trial